BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 25817203)

  • 21. Challenges and opportunities in targeting the menin-MLL interaction.
    Cierpicki T; Grembecka J
    Future Med Chem; 2014 Mar; 6(4):447-62. PubMed ID: 24635524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
    Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
    Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong
    Xu S; Aguilar A; Huang L; Xu T; Zheng K; McEachern D; Przybranowski S; Foster C; Zawacki K; Liu Z; Chinnaswamy K; Stuckey J; Wang S
    J Med Chem; 2020 May; 63(9):4997-5010. PubMed ID: 32338903
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Menin critically links MLL proteins with LEDGF on cancer-associated target genes.
    Yokoyama A; Cleary ML
    Cancer Cell; 2008 Jul; 14(1):36-46. PubMed ID: 18598942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction.
    Xu S; Aguilar A; Xu T; Zheng K; Huang L; Stuckey J; Chinnaswamy K; Bernard D; Fernández-Salas E; Liu L; Wang M; McEachern D; Przybranowski S; Foster C; Wang S
    Angew Chem Int Ed Engl; 2018 Feb; 57(6):1601-1605. PubMed ID: 29284071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MLL-ENL-mediated leukemia initiation at the interface of lymphoid commitment.
    Ugale A; Säwén P; Dudenhöffer-Pfeifer M; Wahlestedt M; Norddahl GL; Bryder D
    Oncogene; 2017 Jun; 36(22):3207-3212. PubMed ID: 28068328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.
    Murai MJ; Pollock J; He S; Miao H; Purohit T; Yokom A; Hess JL; Muntean AG; Grembecka J; Cierpicki T
    Blood; 2014 Dec; 124(25):3730-7. PubMed ID: 25305204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The trithorax protein partner menin acts in tandem with EZH2 to suppress C/EBPα and differentiation in MLL-AF9 leukemia.
    Thiel AT; Feng Z; Pant DK; Chodosh LA; Hua X
    Haematologica; 2013 Jun; 98(6):918-27. PubMed ID: 23349306
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flt3 does not play a critical role in murine myeloid leukemias induced by MLL fusion genes.
    Albouhair S; Morgado E; Lavau C
    PLoS One; 2013; 8(8):e72261. PubMed ID: 23977266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein.
    Murai MJ; Chruszcz M; Reddy G; Grembecka J; Cierpicki T
    J Biol Chem; 2011 Sep; 286(36):31742-8. PubMed ID: 21757704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.
    Jin S; Zhao H; Yi Y; Nakata Y; Kalota A; Gewirtz AM
    J Clin Invest; 2010 Feb; 120(2):593-606. PubMed ID: 20093773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
    Chen Y; Ernst P
    Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.
    Yue L; Du J; Ye F; Chen Z; Li L; Lian F; Zhang B; Zhang Y; Jiang H; Chen K; Li Y; Zhou B; Zhang N; Yang Y; Luo C
    Org Biomol Chem; 2016 Sep; 14(36):8503-19. PubMed ID: 27541268
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NUP98-MLL fusion in human acute myeloblastic leukemia.
    Kaltenbach S; Soler G; Barin C; Gervais C; Bernard OA; Penard-Lacronique V; Romana SP
    Blood; 2010 Sep; 116(13):2332-5. PubMed ID: 20558618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction of MLL amino terminal sequences with menin is required for transformation.
    Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
    Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
    Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
    Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
    Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
    Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MLL-TET1 fusion protein promotes immortalization of myeloid progenitor cells and leukemia development.
    Kim HS; Oh SH; Kim JH; Kim JY; Kim DH; Lee SJ; Choi SU; Park KM; Ryoo ZY; Park TS; Lee S
    Haematologica; 2017 Nov; 102(11):e434-e437. PubMed ID: 28798069
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of embryonic and adult leukemia mouse models driven by MLL-ENL translocation.
    Sinha R; Porcheri C; d'Altri T; González J; Ruiz-Herguido C; Rabbitts T; Espinosa L; Bigas A
    Exp Hematol; 2020 May; 85():13-19. PubMed ID: 32437911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mouse models of MLL leukemia: recapitulating the human disease.
    Milne TA
    Blood; 2017 Apr; 129(16):2217-2223. PubMed ID: 28179274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.